Progenics Pharmaceuticals market cap is $355 m, and annual revenue was $34.99 m in FY 2019

Progenics Pharmaceuticals Gross profit (Q1, 2020)4.7 M

Progenics Pharmaceuticals Gross profit margin (Q1, 2020), %75.1%

Progenics Pharmaceuticals Net income (Q1, 2020)-16.8 M

Progenics Pharmaceuticals EBIT (Q1, 2020)-15.9 M

Progenics Pharmaceuticals Cash, 31-Mar-202029.5 M

Progenics Pharmaceuticals EV378.4 M

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 84.8m | 14.0m | 7.9m | 44.4m | 8.7m | 69.4m | 11.7m | 15.6m | 35.0m |

## Cost of goods sold | 3.2m | ||||||||

## Gross profit | 31.8m | ||||||||

| 91% | ||||||||

## R&D expense | 578.0k | 31.8m | 33.9m | 27.7m | 28.2m | 37.6m | 42.6m | 35.1m | 49.2m |

## General and administrative expense | 18.2m | 14.7m | 14.8m | 14.9m | 18.2m | 23.4m | 24.9m | 29.4m | 47.8m |

## Operating expense total | 18.8m | 48.6m | 48.7m | 42.7m | 46.4m | 60.9m | 67.5m | 64.6m | 98.0m |

## Depreciation and amortization | 939.0k | 545.0k | |||||||

## EBIT | 10.3m | (35.5m) | (43.0m) | 3.4m | (39.3m) | 13.1m | (58.4m) | (66.4m) | (66.2m) |

| 12% | (253%) | (547%) | 8% | (453%) | 19% | (499%) | (425%) | (189%) |

## Interest expense | 65.0k | 60.0k | 46.0k | 51.0k | 52.0k | 493.0k | 4.3m | 2.9m | 2.4m |

## Interest income | 65.0k | 60.0k | 46.0k | 51.0k | 52.0k | ||||

## Pre tax profit | 10.4m | (35.4m) | (42.9m) | 3.4m | (39.3m) | 12.6m | (62.7m) | (69.3m) | (68.5m) |

## Income tax expense | (362.0k) | (989.0k) | (133.0k) | 1.8m | (11.7m) | (1.6m) | 17.0k | ||

## Net Income | 10.4m | (35.4m) | (42.6m) | 4.4m | (39.1m) | 10.8m | (51.0m) | (67.7m) | (68.6m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 10.4m | (35.4m) | (42.6m) | 4.4m | (39.1m) | 10.7m | (51.0m) | (67.7m) | (68.6m) |

## Depreciation and Amortization | 2.1m | 1.3m | 939.0k | 545.0k | 565.0k | 2.1m | 1.1m | 1.5m | 2.4m |

## Accounts Receivable | 767.0k | (5.4m) | 4.1m | 2.8m | (3.4m) | (1.3m) | 892.0k | 204.0k | (12.2m) |

## Inventories | (2.9m) | ||||||||

## Accounts Payable | (3.4m) | (691.0k) | (2.0m) | 58.0k | 2.2m | 243.0k | 2.8m | (2.9m) | 808.0k |

## Cash From Operating Activities | 18.4m | (34.6m) | (36.1m) | 13.7m | (40.1m) | 19.2m | (53.6m) | (46.8m) | (74.7m) |

## Purchases of PP&E | (226.0k) | (767.0k) | (137.0k) | (714.0k) | (370.0k) | (4.3m) | (269.0k) | (817.0k) | (7.2m) |

## Cash From Investing Activities | 74.0k | (277.0k) | 3.0m | 1.8m | (6.5m) | (3.9m) | (232.0k) | (817.0k) | (15.5m) |

## Long-term Borrowings | (5.4m) | (5.8m) | |||||||

## Cash From Financing Activities | 3.7m | 23.7m | 40.1m | 37.9m | 1.4m | 49.6m | 5.5m | 94.7m | (3.9m) |

## Net Change in Cash | 22.2m | (11.3m) | 7.0m | 53.4m | (45.2m) | 64.8m | (48.3m) | 47.1m | (95.7m) |

## Interest Paid | 4.7m | 4.1m | |||||||

## Income Taxes Paid | (13.0k) | 11.0k |

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.1 x |